Project Grant F31AI203132
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $3.589 million on May 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a basic-science foundation for developing tuberculosis treatment-shortening drugs and regimens. The award funds four integrated research projects addressing the biological determinants of treatment duration in Mycobacterium tuberculosis infections. Project 1 examines...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a $3.28 million Project Grant on August 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The four-year research initiative, scheduled for completion on July 31, 2029, focuses on elucidating the mechanisms by which host ubiquitin ligases and deubiquitinases regulate immune responses against Mycobacterium tuberculosis...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $211,875 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test conditional knockdown mutants of Mycobacterium tuberculosis in C3HEB/FEJ mice with human-like tuberculosis pathology. The research analyzes conditional mutants deficient in thioredoxin reductase (TRXB2) and biotin protein ligase (BPL) to determine their ability to...
- The National Institute of Allergy and Infectious Diseases awarded Saint Louis University $192,500 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular mechanisms by which a monocyte chemoattractant protein-1 (MCP-1) promoter polymorphism confers susceptibility to pulmonary tuberculosis infection. The research addresses why approximately 10% of individuals infected with Mycobacterium tuberculosis progress to active pulmonary...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $254,249 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to combine host-directed and pathogen-directed therapeutic approaches against Mycobacterium tuberculosis by exploiting the organism's dependence on cholesterol metabolism. The research will investigate inhibition of two enzymatic targets: MTB's phosphopantetheinyl transferase (PPTT), which...
- National Jewish Health received a $429,546 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate antibiotic regimen efficacy for tuberculosis (TB) treatment. The award, effective August 8, 2025, through July 31, 2027, supports research utilizing SEARCH-TB, an RNA-sequencing platform designed to quantify drug-induced bacterial injury and physiological adaptations in Mycobacterium...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $2,217,926 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the determinants of tuberculosis control, relapse, and reinfection caused by Mycobacterium tuberculosis. The award funds a tri-institutional program project focused on understanding persistent states of TB infection, specifically latent TB infection (LTBI) and...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $110,228 on February 14, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map genetic interactions in mycobacteria and apply those maps to tuberculosis drug discovery and regimen design. The award funds large-scale genetic interaction mapping in Mycobacterium tuberculosis and the model organism M. smegmatis using a CRISPR interference platform for...
- The National Institute of Allergy and Infectious Diseases awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $466,199 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural and mechanistic basis of lipid transport by the atypical membrane transporter RV1410C in Mycobacterium tuberculosis. The research uses cryo-electron microscopy and protein crosslinking in live cells to...
PROFILING CYSTEINE LIGANDABILITY AND ESSENTIALITY IN MYCOBACTERIUM TUBERCULOSIS - PROJECT SUMMARY TUBERCULOSIS (TB) IS A LEADING CAUSE OF DEATH GLOBALLY. TREATMENT IS HAMPERED BY PERSISTENCE OF THE CAUSATIVE BACTERIUM, MYCOBACTERIUM TUBERCULOSIS (MTB), IN DRUG-TOLERANT, NONREPLICATING STATES IN THE HOST. THE DEVELOPMENT OF NEW DRUGS IS COMPLICATED BY AN INCOMPLETE UNDERSTANDING OF DISEASE-RELEVANT PROCESSES IN THE PATHOGEN. CYSTEINE RESIDUES IN THE MTB PROTEOME OFFER A HANDLE ON BOTH CHALLENGES: PLAYING MANY IMPORTANT ROLES IN BACTERIAL PHYSIOLOGY, THEY REPRESENT A LARGELY UNTAPPED LANDSCAPE OF DRUGGABLE SITES IN MTB THAT CAN BE EXPLOITED TO COVALENTLY INHIBIT GROWTH, ADAPTATION, OR PERSISTENCE. THE OBJECTIVE OF THIS PROJECT IS TO ADVANCE TARGET- BASED DRUG DISCOVERY FOR TB BY IDENTIFYING KEY DRUGGABLE CYSTEINES IN MTB, INCLUDING IN NONREPLICATING STATES, AND ELUCIDATING THE MECHANISTIC ROLES THEY PLAY IN ESSENTIAL BACTERIAL PROCESSES. THE PROPOSED RESEARCH APPLIES ACTIVITY-BASED PROTEIN PROFILING TO MAP CYSTEINE LIGANDABILITY ACROSS THE MTB PROTEOME IN BOTH STANDARD CULTURE AND A DISEASE-RELEVANT CASEUM MODEL OF NONREPLICATION. THESE ATLASES WILL REVEAL CYSTEINE SITES SELECTIVELY TARGETABLE BY STEREOSPECIFIC ELECTROPHILES AND IDENTIFY HOW BACTERIAL ADAPTATION TO THE HOST ENVIRONMENT RESHAPES COVALENT DRUGGABILITY. FUNCTIONAL GENETIC SCREENING IN MYCOBACTERIUM SMEGMATIS AND MTB WILL THEN HIGHLIGHT WHICH LIGANDABLE CYSTEINES ARE REQUIRED FOR FITNESS. FINALLY, TAILORED BIOCHEMICAL AND FUNCTIONAL ASSAYS WILL DEFINE THE MECHANISMS BY WHICH HIGH-PRIORITY CYSTEINES GOVERN ESSENTIAL PROCESSES. THIS WORK WILL SHED NEW LIGHT ON THE MTB PROTEOME TO YIELD BOTH FUNDAMENTAL MYCOBACTERIOLOGY INSIGHTS AND PINPOINT NEW HANDLES FOR DRUG DISCOVERY. THE TRAINING PLAN WILL ALSO DEVELOP BROAD EXPERTISE IN GENETIC, BIOCHEMICAL, AND CHEMICAL-PROTEOMIC APPROACHES CENTRAL TO MECHANISTIC INFECTIOUS DISEASE RESEARCH. TRAINING INCLUDES CLOSE COLLABORATION WITH EXPERTS IN MICROBIAL GENETICS, CHEMICAL BIOLOGY, MASS SPECTROMETRY, BIOCHEMISTRY, AND MORE; REGULAR MENTORSHIP FROM DIVERSE SOURCES; AND DEDICATED PRACTICE IN SCIENTIFIC MENTORSHIP, LEADERSHIP, AND COMMUNICATION. THE RESEARCH ENVIRONMENT AT THE ROCKEFELLER UNIVERSITY AND IN THE LAB OF DR. JEREMY ROCK, CHARACTERIZED BY INTERDISCIPLINARY COLLABORATION, STATE-OF-THE-ART FACILITIES, AND SUPPORT FOR PROFESSIONAL DEVELOPMENT, PROVIDES AN EXCEPTIONAL SETTING FOR RIGOROUS SCIENTIFIC TRAINING AND FOR PREPARATION TOWARD AN INDEPENDENT CAREER INVESTIGATING MECHANISMS OF HOST-PATHOGEN INTERACTIONS AND THERAPEUTIC VULNERABILITIES IN INFECTIOUS DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/12/26 | ||
| Not listed | $50.1k | 8/12/26 |